Purdue Pharma and the Opioid Crisis

Summary

Purdue Pharma launched OxyContin in 1996 and marketed it aggressively as carrying a low risk of addiction, a claim later shown to have relied on misrepresented evidence. The resulting prescription-opioid boom is documented as a major contributing factor in a national overdose crisis that has evolved through several distinct phases; Purdue and three executives pleaded guilty to federal criminal charges in 2007, and the company entered bankruptcy in 2019 amid thousands of lawsuits.

What Happened

Purdue Pharma, a privately held pharmaceutical company owned by members of the Sackler family, launched the extended-release opioid painkiller OxyContin in 1996 and marketed it aggressively to physicians, citing claims that its extended-release formulation carried a substantially lower risk of addiction than other opioids — a claim that internal company communications and later litigation showed was not adequately supported, and that drew on a widely miscited 1980 letter to a medical journal editor rather than rigorous clinical evidence of OxyContin’s own addiction risk^[4]. The company’s sales practices, including financial incentives tied to prescription volume and targeted outreach to high-prescribing physicians, contributed to a dramatic increase in opioid prescribing through the late 1990s and 2000s. In 2007, Purdue Frederick Company and three senior executives pleaded guilty to federal criminal charges of misbranding OxyContin, paying over $600 million in fines^[1]. As opioid-related overdose deaths continued rising through subsequent phases of the crisis — increasingly involving heroin and then illicit fentanyl — thousands of lawsuits from state and local governments and individuals led Purdue to file for Chapter 11 bankruptcy in 2019.

Who Was Affected

Patients prescribed OxyContin and other opioids, many of whom developed dependence or addiction, and their families, bore the direct impact; the crisis’s later phases, involving heroin and illicit fentanyl, affected a broader population beyond those originally prescribed Purdue’s product specifically.

Who Was Responsible

Purdue Pharma (see Purdue Pharma) and members of the Sackler family, who controlled the company and its board, directed the marketing strategy at the center of the 2007 and subsequent legal proceedings. Other opioid manufacturers, distributors and pharmacy chains have separately faced litigation over their own roles in the broader crisis, addressed elsewhere in the extensive multi-defendant opioid litigation of the 2010s and 2020s, which this File does not attempt to cover in full.

The Justification

Purdue’s public marketing maintained that OxyContin’s extended-release formulation reduced abuse and addiction potential relative to other opioids; company documents produced in litigation showed internal awareness, within a few years of the drug’s launch, of significant abuse and diversion that was not reflected in the company’s continued marketing claims.

Ideas Behind the File

This case is documented as an example of corporate profit maximization pursued through marketing claims that outpaced the clinical evidence available to support them — a pattern this archive also documents in the earlier tobacco industry litigation, to which opioid-litigation strategy is directly and explicitly indebted.

Institutions

Purdue Pharma directed OxyContin’s marketing and sales strategy under Sackler family ownership and board control; the U.S. Food and Drug Administration approved the original product labeling later found to have overstated its addiction-risk profile, a regulatory decision that has itself been the subject of separate scholarly and journalistic scrutiny.

What Is Certain

That Purdue marketed OxyContin using addiction-risk claims not adequately supported by evidence, and that the company and three executives pleaded guilty to federal misbranding charges in 2007, are established beyond dispute by the plea agreement itself and subsequent litigation discovery^[1].

What Is Disputed

This archive marks Purdue’s specific share of the overall opioid overdose death toll Causation Contested: while Purdue’s marketing is well documented as a significant contributing factor in the crisis’s initial prescription-opioid phase, the crisis’s later and larger waves, driven substantially by heroin and illicit fentanyl largely outside Purdue’s own supply chain, involve separate and additional causal factors that public health researchers and courts have treated as analytically distinct from Purdue’s own conduct, even where connected as part of a broader causal chain.

Human Consequences

Families affected by opioid addiction and overdose death have documented extensive personal, economic and community impact across the United States, with certain regions — including parts of Appalachia and New England — particularly affected during the crisis’s early prescription-opioid phase.

Accountability

Purdue Pharma and three executives pleaded guilty to federal charges in 2007. Following the company’s 2019 bankruptcy filing and a proposed multibillion-dollar settlement that would have released the Sackler family from further personal civil liability, the U.S. Supreme Court ruled in Harrington v. Purdue Pharma (2024) that the bankruptcy code did not permit such non-consensual releases without claimants’ consent, blocking the settlement structure as originally negotiated and returning the parties to further proceedings^[3].

What Changed Afterward

The case contributed to significant changes in U.S. opioid prescribing guidelines, prescription drug monitoring programs, and continued, evolving multi-defendant litigation against other manufacturers, distributors and pharmacies, and the 2024 Supreme Court ruling in particular has reshaped how U.S. bankruptcy law can be used to resolve mass-tort corporate liability going forward.

Sources & Evidence

Last reviewed: January 15, 2025. Found an error? See our corrections policy.